CDK4/6 Inhibitor Rechallenge in ER-Positive Breast Cancer: Understanding Which Patient Populations May Benefit

Key Points: The timing of breast cancer recurrence may aid in predicting response to CDK4/6 inhibitor rechallenge—with longer disease-free...